{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:47:21Z","timestamp":1790948841123,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013881","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000}}],"reference-count":163,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013881.pub2","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T11:24:11Z","timestamp":1685618651000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Interleukin-6 blocking agents for treating COVID-19: a living systematic review"],"prefix":"10.1002","volume":"2023","author":[{"given":"Lina","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre d\u2019Epid\u00e9miologie Clinique, AP-HP, H\u00f4pital H\u00f4tel Dieu, F-75004; Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouba","family":"Assi","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre d\u2019Epid\u00e9miologie Clinique, AP-HP, H\u00f4pital H\u00f4tel Dieu, F-75004; Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Evrenoglou","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S","family":"Buckley","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Henschke","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Probyn","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Riveros","sequence":"additional","affiliation":[{"name":"Centre d\u2019Epid\u00e9miologie Clinique, AP-HP, H\u00f4pital H\u00f4tel Dieu, F-75004; Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricia","family":"Davidson","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Gra\u00f1a","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre d\u2019Epid\u00e9miologie Clinique, AP-HP, H\u00f4pital H\u00f4tel Dieu, F-75004; Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Bonnet","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Jarde","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"\u00c1vila","sequence":"additional","affiliation":[{"name":"Epistemonikos Foundation; Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Hansen","family":"Nejstgaard","sequence":"additional","affiliation":[{"name":"Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark; Department of Clinical Research, University of Southern Denmark; Odense Denmark"},{"name":"Open Patient data Explorative Network (OPEN); Odense University Hospital; Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Menon","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Ferrand","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Kapp","sequence":"additional","affiliation":[{"name":"Institute for Evidence in Medicine (for Cochrane Germany Foundation); Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg; Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Breuer","sequence":"additional","affiliation":[{"name":"Institute for Evidence in Medicine (for Cochrane Germany Foundation); Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg; Freiburg Germany"},{"name":"Cochrane Germany; Cochrane Germany Foundation; Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Schmucker","sequence":"additional","affiliation":[{"name":"Institute for Evidence in Medicine (for Cochrane Germany Foundation); Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg; Freiburg Germany"},{"name":"Cochrane Germany; Cochrane Germany Foundation; Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanina","family":"Sguassero","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu Van","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Devane","sequence":"additional","affiliation":[{"name":"Evidence Synthesis Ireland; Galway Ireland"},{"name":"Cochrane Ireland and HRB-Trials Methodology Research Network; Galway Ireland"},{"name":"University of Galway; Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg J","family":"Meerpohl","sequence":"additional","affiliation":[{"name":"Institute for Evidence in Medicine (for Cochrane Germany Foundation); Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg; Freiburg Germany"},{"name":"Cochrane Germany; Cochrane Germany Foundation; Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Rada","sequence":"additional","affiliation":[{"name":"Epistemonikos Foundation; Santiago Chile"},{"name":"UC Evidence Center, Cochrane Chile Associated Center; Pontificia Universidad Cat\u00f3lica de Chile; Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asbj\u00f8rn","family":"Hr\u00f3bjartsson","sequence":"additional","affiliation":[{"name":"Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark; Department of Clinical Research, University of Southern Denmark; Odense Denmark"},{"name":"Open Patient data Explorative Network (OPEN); Odense University Hospital; Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Grasselli","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Intensive Care and Emergency Department of Anesthesia, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tovey","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ravaud","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre d\u2019Epid\u00e9miologie Clinique, AP-HP, H\u00f4pital H\u00f4tel Dieu, F-75004; Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chaimani","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre d\u2019Epid\u00e9miologie Clinique, AP-HP, H\u00f4pital H\u00f4tel Dieu, F-75004; Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boutron","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre d\u2019Epid\u00e9miologie Clinique, AP-HP, H\u00f4pital H\u00f4tel Dieu, F-75004; Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"10.1002\/14651858.CD013881.pub2-BIB0001|cit1","unstructured":"Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS) clinicaltrials.gov\/ct2\/show\/NCT04412772"},{"issue":"6","key":"10.1002\/14651858.CD013881.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis","volume":"326","author":"WHO REACT Working Group 2021","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD013881.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"e0263591","DOI":"10.1371\/journal.pone.0263591","article-title":"Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial","volume":"17","author":"Branch-Elliman","year":"2022","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0004|cit4","unstructured":"Sarilumab for patients with moderate COVID-19 disease clinicaltrials.gov\/ct2\/show\/NCT04359901"},{"issue":"6","key":"10.1002\/14651858.CD013881.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.cmi.2022.02.027","article-title":"Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study","volume":"28","author":"Broman","year":"2022","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0006|cit6","unstructured":"Use of tocilizumab in the inflammatory phase of COVID-19 \/ new coronavirus disease clinicaltrials.gov\/ct2\/show\/NCT04577534"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0007|cit7","unstructured":"Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2) clinicaltrials.gov\/ct2\/show\/NCT04479358"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis","volume":"6","author":"WHO REACT Working Group 2021","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0009|cit9","unstructured":"Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01) clinicaltrials.gov\/ct2\/show\/NCT04435717"},{"issue":"6","key":"10.1002\/14651858.CD013881.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis","volume":"326","author":"WHO REACT Working Group","year":"2021","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD013881.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S2213-2600(21)00377-5","article-title":"Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial","volume":"9","author":"Declercq","year":"2021","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0012|cit12","unstructured":"Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome] clinicaltrials.gov\/ct2\/show\/"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Derde LPG The REMAP-CAP Investigators Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial medRxiv 2021 [Preprint] https:\/\/doi.org\/10.1101\/2021.06.18.21259133","DOI":"10.1101\/2021.06.18.21259133"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-020-04588-5","article-title":"Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Garcia-Vicu\u00f1a","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0015|cit15","unstructured":"Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection] clinicaltrials.gov\/ct2\/show\/"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0016|cit16","unstructured":"Gordon AC Mouncey PR Al-Beidh F Rowan KM Nichol AD Arabi YM The REMAP-CAP Investigators Interleukin-6 receptor antagonists in critically ill patients with Covid-19 \u2013 preliminary report. medRxiv [Preprint] 2021 10.1101\/2021.01.07.21249390"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically Ill patients with Covid-19","volume":"384","author":"Gordon","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0018|cit18","unstructured":"Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP) clinicaltrials.gov\/ct2\/show\/NCT02735707"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0020|cit20","unstructured":"CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC) clinicaltrials.gov\/ct2\/show\/NCT04331808"},{"issue":"2","key":"10.1002\/14651858.CD013881.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"2102523","DOI":"10.1183\/13993003.02523-2021","article-title":"Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group","volume":"60","author":"Hermine","year":"2022","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0022|cit22","unstructured":"The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation clinicaltrials.gov\/ct2\/show\/NCT04377750"},{"issue":"6","key":"10.1002\/14651858.CD013881.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis","volume":"326","author":"Shankar-Hari","year":"2021","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0024|cit24","unstructured":"Horby PW Pessoa-Amorim G Peto L Brightling CE Sarkar R Thomas K Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial medRxiv 2021 [Preprint] 10.1101\/2021.02.11.21249258"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0025|cit25","unstructured":"A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus) isrctn.com\/ISRCTN50189673"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0026|cit26","unstructured":"Randomised evaluation of COVID-19 therapy (RECOVERY) clinicaltrials.gov\/ct2\/show\/NCT04381936"},{"issue":"10285","key":"10.1002\/14651858.CD013881.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0028|cit28","unstructured":"A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001748-24\/SE"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0029|cit29","unstructured":"A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study clinicaltrials.gov\/ct2\/show\/NCT04412291"},{"issue":"6","key":"10.1002\/14651858.CD013881.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis","volume":"326","author":"Shankar-Hari","year":"2021","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0031|cit31","unstructured":"Jordan S Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500 clinicaltrials.gov\/ct2\/show\/NCT04348500 2021"},{"issue":"5","key":"10.1002\/14651858.CD013881.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Lescure","year":"2021","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Lescure FX Honda H Fowler RA Lazar JS Shi G Wung P Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial medRxiv [Preprint] 2021 10.1101\/2021.02.01.21250769","DOI":"10.1101\/2021.02.01.21250769"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0034|cit34","unstructured":"Sarilumab COVID-19 clinicaltrials.gov\/ct2\/show\/NCT04327388"},{"issue":"10-12","key":"10.1002\/14651858.CD013881.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00011-021-01507-5","article-title":"The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study","volume":"70","author":"Lomakin","year":"2021","journal-title":"Inflammation Research"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0036|cit36","unstructured":"A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 clinicaltrials.gov\/ct2\/show\/NCT04397562"},{"issue":"9","key":"10.1002\/14651858.CD013881.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1097\/CCM.0000000000005591","article-title":"A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation","volume":"50","author":"Lonze","year":"2022","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0038|cit38","unstructured":"A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection clinicaltrials.gov\/ct2\/show\/"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0039|cit39","unstructured":"A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection clinicaltrials.gov\/ct2\/show\/NCT04659772"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(21)00315-5","article-title":"Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial","volume":"4","author":"Mariette","year":"2022","journal-title":"The Lancet Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD013881.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"e0210721","DOI":"10.1128\/aac.02107-21","article-title":"Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial","volume":"66","author":"Merchante","year":"2022","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0042|cit42","unstructured":"Clinical trial of sarilumab in adults with COVID-19 clinicaltrials.gov\/ct2\/show\/NCT04357860"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0043|cit43","unstructured":"A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) clinicaltrials.gov\/ct2\/show\/NCT04320615"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"101409","DOI":"10.1016\/j.eclinm.2022.101409","article-title":"Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)","volume":"47","author":"Rosas","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Rosas IO Br\u00e4u N Waters M Go R Hunter BD Bhagani S Tocilizumab in hospitalized patients with COVID-19 pneumonia medRxiv [Preprint] 2020 10.1101\/2020.08.27.20183442","DOI":"10.1101\/2020.08.27.20183442"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"Feb 25","author":"Rosas","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0047|cit47","unstructured":"Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial trialregister.nl\/trial\/8504"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Rutgers A Westerweel PE van der Holt B Postma S van Vonderen MGA Piersma DP Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients SSRN 2021 [Preprint] 10.2139\/ssrn.3834311","DOI":"10.2139\/ssrn.3834311"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0049|cit49","unstructured":"A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA) clinicaltrials.gov\/ct2\/show\/NCT04372186"},{"issue":"384","key":"10.1002\/14651858.CD013881.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"1","author":"Salama","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0051|cit51","unstructured":"Efficacy of early administration of tocilizumab in COVID-19 patients clinicaltrials.gov\/ct2\/show\/NCT04346355"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0053|cit53","unstructured":"Samsonov M Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) clinicaltrials.gov\/ct2\/show\/NCT04380519"},{"issue":"4","key":"10.1002\/14651858.CD013881.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s40121-021-00543-2","article-title":"Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study)","volume":"10","author":"Sancho-L\u00f3pez","year":"2021","journal-title":"Infectious Diseases and Therapy"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0055|cit55","unstructured":"Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2\/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19] clinicaltrials.gov\/ct2\/show\/"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1093\/cid\/ciac153","article-title":"Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial","volume":"75","author":"Sivapalasingam","year":"2022","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0057|cit57","unstructured":"A study on treatment of COVID-19 patients with study drug along with standard of care trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2020\/05\/025369"},{"issue":"5","key":"10.1002\/14651858.CD013881.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(21)00081-3","article-title":"Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial","volume":"9","author":"Soin","year":"2021","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0059|cit59","unstructured":"Efficacy of tocilizumab on patients with COVID-19 clinicaltrials.gov\/ct2\/show\/NCT04356937"},{"issue":"24","key":"10.1002\/14651858.CD013881.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0061|cit61","unstructured":"Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a \u200eclinical trial study]. en.irct.ir\/trial\/48396"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Talaschian M Akhtari M Mahmoudi M Mostafaei S Jafary M Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a \u200erandomized controlled clinical trial Research Square 2021 [Preprint] 10.21203\/rs.3.rs-463921\/v1","DOI":"10.21203\/rs.3.rs-463921\/v1"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0063|cit63","unstructured":"Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS) clinicaltrials.gov\/ct2\/show\/NCT04403685"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"Veiga","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0065|cit65","unstructured":"A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19) chictr.org.cn\/showprojen.aspx?proj=49409"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Wang D Fu B Peng Z Yang D Han M Li M Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial Available at SSRN: papers.ssrn.com\/sol3\/papers.cfm?abstract_id=3667681 [Preprint with The Lancet] 2020 10.2139\/ssrn.3667681","DOI":"10.2139\/ssrn.3667681"},{"issue":"3","key":"10.1002\/14651858.CD013881.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11684-020-0824-3","article-title":"Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial","volume":"15","author":"Wang","year":"2021","journal-title":"Frontiers in Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Albuquerque AM Tramujas L Sewanan LR Brophy JM Tocilizumab in COVID-19 \u2013 A Bayesian reanalysis of RECOVERY medRxiv 2021 [Preprint] 10.1101\/2021.06.15.21258966","DOI":"10.1101\/2021.06.15.21258966"},{"issue":"4","key":"10.1002\/14651858.CD013881.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jinf.2020.07.008","article-title":"Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis","volume":"81","author":"Rossotti","year":"2020","journal-title":"Journal of Infection"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"155662","DOI":"10.1016\/j.cyto.2021.155662","article-title":"Assessing the potential correlation of polymorphisms in the IL6R with relative IL6 elevation in severely ill COVID-19 patients'","volume":"148","author":"Smieszek","year":"2021","journal-title":"Cytokine"},{"issue":"3","key":"10.1002\/14651858.CD013881.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/CCM.0000000000005229","article-title":"Prognostic and predictive biomarkers in patients With Coronavirus Disease 2019 treated with tocilizumab in a randomized controlled trial","volume":"50","author":"Tom","year":"2022","journal-title":"Critical Care Medicine"},{"issue":"18","key":"10.1002\/14651858.CD013881.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1016\/S0735-1097(21)04383-7","article-title":"Effect of tocilizumab on cardiac injury and dysfunction in COVID-19","volume":"77","author":"Zafar","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0073|cit73","unstructured":"Effectiveness of Interleukin-6 receptor inhibitors in the management of patients with severe SARS-CoV-2 pneumonia: An open-Label multicenter sequential randomized controlled trial clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001275-32\/DK"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0074|cit74","unstructured":"EUCTR2020-001290-74-ES www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-001290-74"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0075|cit75","unstructured":"A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia clinicaltrialsregister.eu\/\/ctr-search\/trial\/2020-001408-41\/DE"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0076|cit76","unstructured":"COVID 19: Experimental use of tocilizumab (Roactemra\u00ae) in severe SARS-CoV-2 related pneumonia. clinicaltrialsregister.eu\/\/ctr-search\/trial\/2020-001770-30\/BE"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0077|cit77","unstructured":"Tocilizumab in the treatment of Coronavirus induced disease (COVID-19) (CORON-ACT) clinicaltrials.gov\/ct2\/show\/NCT04335071"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0078|cit78","unstructured":"Study for the use of the IL-6 Inhibitor clazakizumab in patients with life-threatening COVID-19 infection clinicaltrials.gov\/ct2\/show\/NCT04381052"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0079|cit79","unstructured":"Siltuximab in viral ARds. Study (SILVAR) clinicaltrials.gov\/ct2\/show\/NCT04616586"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0080|cit80","unstructured":"Theranostic implication of complementary medicines against interleukin receptors and Gp-130 proteins clinicaltrials.gov\/ct2\/show\/NCT04690920"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0081|cit81","unstructured":"Tocilizumab for the treatment of COVID-19 in intensive care patients: effect on days free of ventilatory support anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=379640&isReview=true"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0082|cit82","unstructured":"Efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia on steroid therapy: A prospective, randomized, double blind placebo-controlled trial ctri.nic.in\/Clinicaltrials\/showallp.php?mid1=50303&EncHid=&userName=Tocilizumab"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0083|cit83","unstructured":"A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients with severe COVID-19 pneumonia clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-001390-76"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0084|cit84","unstructured":"An open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001767-86\/IE"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0085|cit85","unstructured":"Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19 patients www.irct.ir\/trial\/48024"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0086|cit86","unstructured":"A comparative study of the effects of tocilizumab, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm www.irct.ir\/trial\/48583"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0087|cit87","unstructured":"Efficacy of Tocilizumab in Hospitalized Patients with COVID-19: An open-label placebo-controlled clinical study www.irct.ir\/trial\/56613"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0088|cit88","unstructured":"Tocilizumab for the treatment of cytokine release syndrome in patients with COVID-19 (SARS-CoV-2 infection) clinicaltrials.gov\/ct2\/show\/NCT04361552"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0089|cit89","unstructured":"Study of the efficacy and safety of a single administration of Olokizumab vs. placebo in addition to standard treatment in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection (COVID-19) clinicaltrials.gov\/ct2\/show\/NCT04452474"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0090|cit90","unstructured":"Clazakizumab vs. placebo - COVID-19 infection clinicaltrials.gov\/ct2\/show\/NCT04494724"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0091|cit91","unstructured":"Study of efficacy of different treatment regimens of Olokizumab (RESET) clinicaltrials.gov\/ct2\/show\/NCT05187793"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"n436","DOI":"10.1136\/bmj.n436","article-title":"Severe covid-19 pneumonia: pathogenesis and clinical management","volume":"372","author":"Attaway","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0093|cit93","first-page":"153","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"BMJ Mental Health"},{"issue":"6515","key":"10.1002\/14651858.CD013881.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"issue":"4","key":"10.1002\/14651858.CD013881.pub2-BIB0095|cit95","first-page":"2136","article-title":"Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials","volume":"92","author":"Boppana","year":"2022","journal-title":"Monaldi Archives for Chest Disease"},{"issue":"12","key":"10.1002\/14651858.CD013881.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.7326\/M20-5261","article-title":"The COVID-NMA project: building an evidence ecosystem for the COVID-19 pandemic","volume":"173","author":"Boutron","year":"2020","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013881.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1007\/s11192-021-03900-7","article-title":"Day-to-day discovery of preprint-publication links","volume":"126","author":"Cabanac","year":"2021","journal-title":"Scientometrics"},{"issue":"10","key":"10.1002\/14651858.CD013881.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1016\/S2665-9913(20)30287-3","article-title":"The conundrum of interleukin-6 blockade in COVID-19","volume":"2","author":"Campochiaro","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0099|cit99","doi-asserted-by":"crossref","unstructured":"COVID-19 use causes tocilizumab shortage Cancer Discovery 2021 11 12 2950 doi.org\/10.1158\/2159-8290.CD-NB2021-0386","DOI":"10.1158\/2159-8290.CD-NB2021-0386"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2020-218323","article-title":"Preliminary predictive criteria for COVID-19 cytokine storm","volume":"80","author":"Caricchio","year":"2021","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD013881.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/1536867X1801800310","article-title":"Allowing for informative missingness in aggregate data meta-analysis with continuous or binary outcomes: extensions to metamiss","volume":"18","author":"Chaimani","year":"2018","journal-title":"Stata Journal"},{"issue":"4","key":"10.1002\/14651858.CD013881.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"2003006","DOI":"10.1183\/13993003.03006-2020","article-title":"Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome","volume":"56","author":"Chen","year":"2020","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD013881.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial","volume":"9","author":"CORIMUNO-19 Collaborative group","year":"2021","journal-title":"Lancet Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013881.pub2-BIB0105|cit105","first-page":"195","article-title":"[The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]","volume":"112","author":"Cruciani","year":"2021","journal-title":"Recenti Progressi in Medicina"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0106|cit106","doi-asserted-by":"crossref","unstructured":"Evrenoglou T Boutron I Chaimani A metaCOVID: An R-Shiny application for living meta-analyses of COVID-19 trials medRxiv 2021 [Preprint] doi.org\/10.1101\/2021.09.07.21263207","DOI":"10.1101\/2021.09.07.21263207"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41590-020-00840-x","article-title":"Untuned antiviral immunity in COVID-19 revealed by temporal type I\/III interferon patterns and flu comparison","volume":"22","author":"Galani","year":"2021","journal-title":"Nature Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaci.2020.09.018","article-title":"IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study","volume":"147","author":"Galv\u00e1n-Rom\u00e1n","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD013881.pub2-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013881","article-title":"Interleukin-6 blocking agents for treating COVID-19: a living systematic review","author":"Ghosn","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0110|cit110","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"8","key":"10.1002\/14651858.CD013881.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9.","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","article-title":"Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19","volume":"146","author":"Herold","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.2147\/JIR.S322831","article-title":"Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future","volume":"14","author":"Hertanto","year":"2021","journal-title":"Journal of Inflammation Research"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0114|cit114","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook 2021"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41232-020-00146-3","article-title":"How COVID-19 induces cytokine storm with high mortality","volume":"40","author":"Hojyo","year":"2020","journal-title":"Inflammation and Regeneration"},{"issue":"8","key":"10.1002\/14651858.CD013881.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013881.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"e0248132","DOI":"10.1371\/journal.pone.0248132","article-title":"Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)","volume":"16","author":"Juul","year":"2021","journal-title":"PLoS One"},{"issue":"9","key":"10.1002\/14651858.CD013881.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013881.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"e20190347. Erra","DOI":"10.1084\/jem.20190347","article-title":"Historical overview of the interleukin-6 family cytokine","volume":"217","author":"Kang","year":"2020","journal-title":"Journal of Experimental Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0120|cit120","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215266","article-title":"Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19","volume":"Feb 2021","author":"Khan","year":"2021","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"583897","DOI":"10.3389\/fmed.2020.583897","article-title":"IL-6 Inhibition in critically ill COVID-19 patients is associated with increased secondary infections","volume":"7","author":"Kimmig","year":"2020","journal-title":"Frontiers in Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"k3802","DOI":"10.1136\/bmj.k3802","article-title":"Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews","volume":"362","author":"Kirkham","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"ofab608","DOI":"10.1093\/ofid\/ofab608","article-title":"Safety and efficacy of Tocilizumab 4 or 8 mg\/kg in hospitalized patients with moderate to severe Coronavirus disease 2019 pneumonia: A randomized clinical trial","volume":"9","author":"Kumar","year":"2022","journal-title":"Open Forum Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD013881.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013881.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jaci.2020.07.009","article-title":"IL-6-based mortality risk model for hospitalized patients with COVID-19","volume":"146","author":"Laguna-Goya","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"7821","key":"10.1002\/14651858.CD013881.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1002\/14651858.CD013881.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2665-9913(20)30275-7","article-title":"COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study","volume":"2","author":"Manson","year":"2020","journal-title":"The Lancet Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD013881.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/sim.6365","article-title":"Allowing for uncertainty due to missing continuous outcome data in pairwise and network meta-analysis","volume":"34","author":"Mavridis","year":"2015","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013881.pub2-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/eb-2014-101899","article-title":"Missing outcome data in meta-analysis","volume":"21","author":"Mavridis","year":"2018","journal-title":"Evidence Based Mental Health"},{"issue":"10229","key":"10.1002\/14651858.CD013881.pub2-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0131|cit131","unstructured":"Nejstgaard CH Fabbri A Hr\u00f3bjartsson A Training manual for RoB 2 risk of bias assessment in COVID-19 trials eligible for the COVID-19 living network meta-analysis Available from zenodo.org\/record\/4928079 10.5281\/zenodo.4928079"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s12916-020-01880-8","article-title":"Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study","volume":"18","author":"Oikonomidi","year":"2020","journal-title":"BMC Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan \u2014 a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0134|cit134","unstructured":"Pan American Health Organization Ongoing living update of potential COVID-19 therapeutics options: summary of evidence: rapid review Available at iris.paho.org\/handle\/10665.2\/52719."},{"issue":"5","key":"10.1002\/14651858.CD013881.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: a storm is raging","volume":"130","author":"Pedersen","year":"2020","journal-title":"Journal of Clinical Investigation"},{"issue":"2","key":"10.1002\/14651858.CD013881.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"557","DOI":"10.18632\/aging.203834","article-title":"Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis","volume":"14","author":"Peng","year":"2022","journal-title":"Aging"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jclinepi.2021.09.022","article-title":"Secondary electronic sources demonstrated very good sensitivity for identifying studies evaluating interventions for COVID-19","volume":"141","author":"Pierre","year":"2022","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2022.07.015","article-title":"GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions","volume":"150","author":"Sch\u00fcnemann","year":"2022","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0140|cit140","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"17","key":"10.1002\/14651858.CD013881.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for covid-19: living systematic review and network meta-analysis","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"issue":"13","key":"10.1002\/14651858.CD013881.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"7475","DOI":"10.26355\/eurrev_202007_21916","article-title":"A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients","volume":"24","author":"Solis-Garc\u00eda Del Pozo","year":"2020","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD013881.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013881.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"e0203","DOI":"10.1097\/CCE.0000000000000203","article-title":"The association of inflammatory cytokines in the pulmonary pathophysiology of respiratory failure in critically ill patients with Coronavirus Disease 2019","volume":"2","author":"Stukas","year":"2020","journal-title":"Critical Care Explorations"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"100228","DOI":"10.1016\/j.lana.2022.100228","article-title":"Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study","volume":"11","author":"Stukas","year":"2022","journal-title":"Lancet Regional Health \u2013 Americas"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"2","key":"10.1002\/14651858.CD013881.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cmi.2020.10.036","article-title":"Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis","volume":"27","author":"Tleyjeh","year":"2021","journal-title":"Clinical Microbiology and Infection"},{"issue":"5","key":"10.1002\/14651858.CD013881.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.jaci.2021.02.021","article-title":"IL-6-based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts","volume":"147","author":"Utrero-Rico","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"21","key":"10.1002\/14651858.CD013881.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"E771","DOI":"10.1503\/cmaj.210531","article-title":"Managing drug shortages during a pandemic: tocilizumab and COVID-19","volume":"193","author":"Verma","year":"2021","journal-title":"CMAJ"},{"issue":"3","key":"10.1002\/14651858.CD013881.pub2-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"48","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"Journal of Statistical Software"},{"issue":"12","key":"10.1002\/14651858.CD013881.pub2-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2665-9913(20)30343-X","article-title":"Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study","volume":"2","author":"Webb","year":"2020","journal-title":"The Lancet Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD013881.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/sim.3008","article-title":"Allowing for uncertainty due to missing data in meta-analysis - part 1: two-stage methods","volume":"27","author":"White","year":"2008","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0155|cit155","unstructured":"World Health Organization Rolling updates on coronavirus diseases (COVID-19) Available from www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/events-as-they-happen"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0156|cit156","unstructured":"World Health Organization Clinical management of severe acute respiratory infection when COVID-19 is suspected Available from who.int\/publications\/i\/item\/10665-332299"},{"issue":"6","key":"10.1002\/14651858.CD013881.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis","volume":"326","author":"Shankar-Hari","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD013881.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection","year":"2020","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0159|cit159","unstructured":"Coronavirus Symptoms (COVID-19) www.worldometers.info\/coronavirus\/coronavirus-symptoms\/"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1080\/22221751.2022.2059405","article-title":"Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis","volume":"11","author":"Yu","year":"2022","journal-title":"Emerging Microbes & Infections"},{"issue":"1","key":"10.1002\/14651858.CD013881.pub2-BIB0161|cit161","first-page":"14","article-title":"Life-threatening COVID-19: Defective interferons unleash excessive inflammation","volume":"1","author":"Zhang","year":"2020","journal-title":"New York Medical Journal"},{"issue":"11","key":"10.1002\/14651858.CD013881.pub2-BIB0162|cit162","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013769","article-title":"Interventions for the prevention and treatment of COVID-19: a living mapping of research and living network meta-analysis","author":"Boutron","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013881.pub2-BIB0163|cit163","unstructured":"Ghosn L Boutron I Interleukin (IL)-6 blocking agents for the treatment of COVID-19. A living systematic review. PROSPERO 2020 CRD42020214700 Available from: www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020214700"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:11:12Z","timestamp":1735517472000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013881.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Emergency and Critical Care Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":163,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013881.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}